Oncolytics Biotech Inc. · NASDAQ:ONCY

Oncolytics Biotech — Investor Presentation (June 2017)

29 slides from Oncolytics Biotech's investor presentation, June 2017

  1. Slide 1: Investor Presentation

    Investor Presentation June 2017 www.oncolyticsbiotech.com TSX ONC OTCQX ONCYF

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains certain forward looking statements relating to the company’s business prospects and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on management’s current expectations and beliefs and are su

  3. Slide 3: Rapid Recent Progress

    Rapid Recent Progress  REOLYSIN® statistically significantly increased overall survival (OS) in metastatic breast cancer (REO + paclitaxel vs. paclitaxel alone)  Granted “Fast Track” designation by the FDA  Strengthened management team: C-Suite and Business Development  Announced collaboration w

  4. Slide 4: What is REOLYSIN?

    What is REOLYSIN®?  First-in-class systemically administered immuno- oncology viral agent for solid tumors and heme malignancies  Non-pathogenic proprietary isolate of the unmodified reovirus 4

  5. Slide 5: REOLYSIN Mechanism of Action

    REOLYSIN® Mechanism of Action In Normal Cells In non-cancer cells Reolysin enters the cells but is unable to replicate and the virus is actively cleared. Pelareorep 1. Reolysin selectively replicates in administered to permissive cancer cells. Upon patients via IV In Cancer Cells virus replication,

  6. Slide 6: What does REOLYSIN do?

    What does REOLYSIN® do? 1. Kills cancer cells stressed by chemo and/or radiation 2. Induces PD-1 & PDL-1 expression on T-cells and tumor-cells 3. Enhances IMiD targeting 4. Potentiator for all agents affecting both innate and adaptive immunity by making cold tumors hot 6

  7. Slide 7: REOLYSIN MOA: Lessons Learned

    REOLYSIN® MOA: Lessons Learned • OS results support Mechanism of Action (MOA) • OS trumps PFS (progression free survival) • We’re not the only ones o Opdivo®, Tecentriq® and Ipilimumab® have been approved on OS Progression Free Survival Overall Survival Melanoma Ipilimumab treated with ICI Ipilimuma

  8. Slide 8: Clinical Data & Development Plan

    Clinical Data & Development Plan

  9. Slide 9: Clinical Development Plan: Pathways

    Clinical Development Plan: Pathways The clinical development plan addresses drug combinations that can potentially boost each response of the MOA 1. Path 1 - Chemo combinations (direct cell lysis): The basis for our metastatic breast cancer registration pathway. 2. Path 2 - Immunotherapy combination

  10. Slide 10: Path 1: Chemotherapy Combinations

    Path 1: Chemotherapy Combinations Metastatic Breast Cancer Regulatory Status o Statistically significant phase 2 OS data o Seeking scientific advice - potential for Breakthrough Designation o Preparing for End-of-Phase 2 Meeting o Preparing registration pathway Metastatic Pancreatic Cancer (1st Line

  11. Slide 11: Path 1: Chemo-Combo / Breast Cancer

    Path 1: Chemo-Combo / Breast Cancer (IND-213) Phase 2 Design (IND-213) Phase 2 Data • Randomized, non-blinded study, with IV • ORR and PFS similar in both groups administered REOLYSIN® given in • Statistically significant improvement combination with paclitaxel versus paclitaxel alone in median OS:

  12. Slide 12: Path 1: Chemo-Combo / Breast Cancer

    Path 1: Chemo-Combo / Breast Cancer Statistically significantly increased overall survival in metastatic breast cancer in ITT group Test n=36 Control n=38 HR = 0.65 p = 0.1 (powered to 90%) Canadian Cancer Trials Group Test = REO + paclitaxel Control = paclitaxel 12

  13. Slide 13: Path 1: Chemo-Combo / Breast Cancer

    Path 1: Chemo-Combo / Breast Cancer Doubled overall survival APC wild type patients Test n=31 Control n=29 HR = 0.53 p = 0.03 Canadian Cancer Trials Group Test = REO + paclitaxel Control = paclitaxel 13

  14. Slide 14: Path 1: Chemo-Combo / Breast Cancer

    Path 1: Chemo-Combo / Breast Cancer Key Learnings  Consistent with other approved I/O therapies, REOLYSIN® acts as an immune therapy agent, often with no meaningful improvement in either PFS or ORR  Has the potential to work synergistically with paclitaxel Next Steps  Seeking scientific advice -

  15. Slide 15: Path 1: Chemo-Combo / Breast Cancer

    Path 1: Chemo-Combo / Breast Cancer 3,560,570 breast cancer prevalence, US 2016 115,405 2,599,216 addressable patient population on Patients with HR+/HER2- Subtype target therapies (74% of mBC patients) 155,953 Patients diagnosed with stage IV Source: https://seer.cancer.gov/statfacts/html/breast.ht

  16. Slide 16: Path 1: Supporting OS as Registration Endpoint

    Path 1: Supporting OS as Registration Endpoint Doubling 2-year survival in phase 2 studies Single Arm (REO 017) Randomized Intention-to-Treat (NCI-8601) Randomized Excluding Crossover o REO + Gemcitabine o Carbotax + REO (n=36) o Carbotax + REO (n=36) (n=34) o Carbotax (n=37) o Carbotax (n=20) Reo +

  17. Slide 17: Path 2: Immunotherapy Combinations

    Path 2: Immunotherapy Combinations REO + Pembrolizumab (anti-PD-1 antibody) in pancreatic cancer (REO 024) o Establish safety profile o Final analysis in 2017 Future potential collaborations pending Rajani, Viruses 2015, 7:588; Noonan, Mol Ther 2016; Rajani, Mol Ther 2016,24:166 17

  18. Slide 18: Path 3: Targeted/IMiD Combinations

    Path 3: Targeted/IMiD Combinations Enhancement of Innate Immune Response: REO + Pomalidomide in multiple myeloma REOLYSIN® + IMiDs o Establish safety profile REOLYSIN® alone o Ongoing collaboration with Celgene & Myeloma UK Activation of NK cells o Combined with Revlimid® & Imnovid® as a rescue trea

  19. Slide 19: Safety, Manufacturing & Intellectual Property

    Safety, Manufacturing & Intellectual Property

  20. Slide 20: REOLYSIN and Safety

    REOLYSIN® and Safety Intravenous local  1,100+ patients treated, 900+ intravenously  No maximum tolerated dose (MTD) reached to date Monotherapy Toxicity Symptoms  Toxicities have generally been mild (grade 1 or 2) and included chills, fever, headache, cough, myalgia, runny nose, sore throat, fat

  21. Slide 21: Manufacturing

    Manufacturing  Final formulation produced at 100L scale under cGMP  Commercial scale manufacturing agreement with SAFC 21

  22. Slide 22: Patent Portfolio

    Patent Portfolio  More than 415 patents issued worldwide, including 61 US and 20 Canadian  Reovirus issue patent claims cover: • Compositions of matter comprising reovirus • Through 2028 • Pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases • Combination therapy

  23. Slide 23: Corporate & Financial

    & Corporate & Financial C)ncoryrics

  24. Slide 24: Experienced Leadership

    Experienced Leadership Management Non-Executive Directors Matt Coffey, PhD, MBA Wayne Pisano, MBA Co-founder, Director, Chairman of the Board, Oncolytics President & CEO Former President, Sanofi Pasteur Angela Holtham, MBA, ICD.D Kirk Look, CA Nabisco Chief Financial Officer Hospital for Sick Childr

  25. Slide 25: Milestones

    Milestones Event Timing New Leadership Team Collaboration with Myeloma UK & Celgene More than doubled 2 year survival in pancreatic cancer Statistically significantly increased OS in metastatic breast cancer Fast Track Designation End-of-Phase 2 Meeting for mBC Mid ’17 Regulatory milestones (includi

  26. Slide 26: Market and Capital Data

    Market and Capital Data OTCQX: ONCYF Exchanges TSX: ONC USD $60.1 M Market Cap (June 1, 2017) CDN $82.1 M Shares Outstanding (June 1, 2017) 139,083,722 Warrants (June 1, 2017) 16,445,000 Options (March 31, 2017) 8,611,327 Restricted/performance share units (March 31, 2017) 2,261,169 Fully Diluted (J

  27. Slide 27: Investment Highlights

    Investment Highlights  REOLYSIN® statistically significantly increased overall survival (OS) in metastatic breast cancer (REO + paclitaxel vs. paclitaxel alone)  Granted “Fast Track” designation by the FDA  Strengthened management team: C-Suite and Business Development  Unpartnered immuno-oncolo

  28. Slide 28: Investor Presentation

    Investor Presentation www.oncolyticsbiotech.com TSX ONC OTCQX ONCYF

  29. Slide 29: The Landscape

    The Landscape Amgen AZ / Medimmune Bristol-Myers Squibb BioVEx Upfront $425M Omnis Pharma Undisclosed PsiOxus Upfront $50M Milestones $575M Milestones $886M Ph 3 oncolytic vaccine for H&N and Combine IO portfolio with oncolytic virus NG-348, a pre-clinical oncolytic virus for melanoma programme soli

Oncolytics Biotech — Investor Presentation (June 2017) on 6ix